Süleyman Karaköse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Süleyman Karaköse has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Guney
Konya Şehir Hastanesi
11 shared publications - Beyza Doğan
Department of Nephrology, University Health of Sciences, Konya City Hospital, Konya
8 shared publications - Dilek Torun
Adana Dr Turgut Noyan Teaching and Research Center, Department of Nephrology, Faculty of Medicine, Baskent University, 06790 Adana, Türkiye
5 shared publications - Ebru Gök Oğuz
Department of Nephrology, Etlik City Hospital, Ankara, Türkiye
5 shared publications - Fatih Ergül
Division of Nephrology, Department of Internal Medicine, University of Health Sciences, Konya City Hospital, Konya, Türkiye
5 shared publications - Murat Duranay
Department of Nephrology, Ankara Training and Research Hospital, Health Sciences University, 06230 Ankara, Türkiye
5 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5758
Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- 23 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5758
Open AccessHyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- Open Access
- 24 June 2026
- Published by MDPI AG in Preprints.org
Hyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- 24 June 2026
- Published by MDPI AG in Preprints.org
Open AccessHyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- Open Access
- 8 May 2026
- Published by MDPI AG in Preprints.org
Hyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort
Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.
- 8 May 2026
- Published by MDPI AG in Preprints.org
Open AccessHyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort
Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.
- Open Access
- 20 February 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (1) , 14-19
Effect of iron sucrose on intradialytic blood pressure in patients receiving maintenance hemodialysis treatment
Aims: There are studies showing that IV iron sucrose is vasoactive and causes changes in intradialytic blood pressure in hemodialysis patients. Intradialytic hypotension has been associated with vascular thrombosis, inadequate dialysis, and increased mortality. Intradialytic hypertension, has been shown in some studies to be associated with increased cardiovascular mortality and an increase in the frequency of hospitalization. In this study, we aimed to investigate the effect of iron sucrose on intradialytic blood pressure in hemodialysis patients.Methods: In this study, 59 patients undergoing hemodialysis three times a week had their blood pressure measured before hemodialysis and recorded at minute 0. 100 mg/5 ml iron sucrose was administered as an IV infusion during the first 30 minutes of dialysis treatment, and blood pressure was measured and recorded every 30 minutes. The same patient's blood pressure was measured every 30 minutes during the next hemodialysis session without iron sucrose treatment. Results: Intradialytic hypotension developed in two different patient; one patient in the session in which iron sucrose was given and one in the session in which iron sucrose was not given. There was no significant difference in intradialytic hypertension between the groups according to all three definitions of intradialytic hypertension (p=0.134; 0.523; and 1, respectively).Conclusion: We found that iron sucrose administration does not cause both intradialytic hypotension and intradialytic hypertension.
- 20 February 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (1) , 14-19
Open AccessEffect of iron sucrose on intradialytic blood pressure in patients receiving maintenance hemodialysis treatment
Aims: There are studies showing that IV iron sucrose is vasoactive and causes changes in intradialytic blood pressure in hemodialysis patients. Intradialytic hypotension has been associated with vascular thrombosis, inadequate dialysis, and increased mortality. Intradialytic hypertension, has been shown in some studies to be associated with increased cardiovascular mortality and an increase in the frequency of hospitalization. In this study, we aimed to investigate the effect of iron sucrose on intradialytic blood pressure in hemodialysis patients.Methods: In this study, 59 patients undergoing hemodialysis three times a week had their blood pressure measured before hemodialysis and recorded at minute 0. 100 mg/5 ml iron sucrose was administered as an IV infusion during the first 30 minutes of dialysis treatment, and blood pressure was measured and recorded every 30 minutes. The same patient's blood pressure was measured every 30 minutes during the next hemodialysis session without iron sucrose treatment. Results: Intradialytic hypotension developed in two different patient; one patient in the session in which iron sucrose was given and one in the session in which iron sucrose was not given. There was no significant difference in intradialytic hypertension between the groups according to all three definitions of intradialytic hypertension (p=0.134; 0.523; and 1, respectively).Conclusion: We found that iron sucrose administration does not cause both intradialytic hypotension and intradialytic hypertension.
- Open Access
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (1) , 67-71
The Relationship Between Mucociliary Clearance Time and Peritonitis Frequency in Patients Receiving Peritoneal Dialysis
Background: The present study sought to explore the association between nasal mucociliary clearance time (MCT) and the frequency of peritonitis among patients with chronic kidney disease (CKD) treated by peritoneal dialysis (PD). Methods: This cross-sectional study enrolled 24 patients with CKD treated by PD and 24 healthy volunteers. Nasal muco ciliary function was assessed using the saccharin transit time test. In this procedure, a saccharin particle with a 1 mm diameter was meticulously placed on the anteromedial surface of the inferior nasal concha. The 2 groups were compared based on their mean MCT. Within the patient group, the number of peritonitis cases in the last year was evaluated, and the correlation between MCT and the occurrence of peritonitis was analyzed. Results: The patient group consisted of 15 females and 9 males, with a mean age of 52.6 years. The control group included 14 females and 10 males, with a mean age of 47.5 years. The mean duration of PD among the followed cohort was 20 months, ranging from 3 to 190 months. The comparison of mean MCT between patients with a history of peritonitis and those with out peritonitis did not reveal a statistically significant difference (P = .333). However, the neutrophil-to-lymphocyte ratio was significantly elevated in the group exhibiting prolonged MCT (P = .046). Conclusion: Although this study found no statistically significant direct relationship between peritonitis incidence and MCT, the research aimed to evaluate MCT as a potential indicator of susceptibility to respiratory tract infections, which play a role in the development of peritonitis. Cite this article as: Doğan B, Ergül F, Basut R, et al. The relationship between mucociliary clearance time and peritonitis frequency in patients receiving peritoneal dialysis. Turk J Nephrol. 2026;35(1):67-71.
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (1) , 67-71
Open AccessThe Relationship Between Mucociliary Clearance Time and Peritonitis Frequency in Patients Receiving Peritoneal Dialysis
Background: The present study sought to explore the association between nasal mucociliary clearance time (MCT) and the frequency of peritonitis among patients with chronic kidney disease (CKD) treated by peritoneal dialysis (PD). Methods: This cross-sectional study enrolled 24 patients with CKD treated by PD and 24 healthy volunteers. Nasal muco ciliary function was assessed using the saccharin transit time test. In this procedure, a saccharin particle with a 1 mm diameter was meticulously placed on the anteromedial surface of the inferior nasal concha. The 2 groups were compared based on their mean MCT. Within the patient group, the number of peritonitis cases in the last year was evaluated, and the correlation between MCT and the occurrence of peritonitis was analyzed. Results: The patient group consisted of 15 females and 9 males, with a mean age of 52.6 years. The control group included 14 females and 10 males, with a mean age of 47.5 years. The mean duration of PD among the followed cohort was 20 months, ranging from 3 to 190 months. The comparison of mean MCT between patients with a history of peritonitis and those with out peritonitis did not reveal a statistically significant difference (P = .333). However, the neutrophil-to-lymphocyte ratio was significantly elevated in the group exhibiting prolonged MCT (P = .046). Conclusion: Although this study found no statistically significant direct relationship between peritonitis incidence and MCT, the research aimed to evaluate MCT as a potential indicator of susceptibility to respiratory tract infections, which play a role in the development of peritonitis. Cite this article as: Doğan B, Ergül F, Basut R, et al. The relationship between mucociliary clearance time and peritonitis frequency in patients receiving peritoneal dialysis. Turk J Nephrol. 2026;35(1):67-71.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (3) , e20251460
The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease
SUMMARY OBJECTIVE: The aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population. METHODS: We retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data. RESULTS: Following 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure. CONCLUSION: Sodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (3) , e20251460
Open AccessThe effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease
SUMMARY OBJECTIVE: The aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population. METHODS: We retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data. RESULTS: Following 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure. CONCLUSION: Sodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.
- Open Access
- 26 November 2025
- Published by Ataturk Universitesi in Pharmata
- Vol. 5 (3) , 77-82
Examining the Relationship Between PWV Change and eGFR Change Over Time in Chronic Kidney Disease Patients
Objective: This study aimed to investigate the longitudinal relationship between pulse wave velocity (PWV), a measure of arterial stiffness, and estimated glomerular filtration rate (eGFR), an indicator of renal function, in patients with chronic kidney disease (CKD). Methods: A total of 55 CKD patients (Stage 3–5), not on renal replacement therapy, were prospectively followed for approximately four years. PWV and eGFR were measured at baseline and at the end of follow-up. Patients were divided into two groups based on eGFR progression: stable and progressive decline. Demographic, clinical, and laboratory data were collected. The association between changes in PWV (ΔPWV) and eGFR (ΔeGFR) was analyzed. Results: No significant correlation was found between changes in PWV and changes in eGFR (P>.05). While there was a significant decline in eGFR in the progressive group compared to the stable group (P=.001), ΔPWV did not significantly differ between the groups. Variables such as age, blood pressure, and baseline PWV were not significantly different between groups. Parathormone and phosphorus levels were higher, and hemoglobin and albumin levels were lower in patients with eGFR progression. Conclusion: Over a four-year follow-up, changes in arterial stiffness (PWV) were not significantly associated with changes in renal function (eGFR) among CKD patients. The lack of correlation suggests that separate pathophysiological mechanisms may govern vascular stiffness and kidney function deterioration. Further studies, including molecular-level analyses, are required to clarify these complex interactions.
- 26 November 2025
- Published by Ataturk Universitesi in Pharmata
- Vol. 5 (3) , 77-82
Open AccessExamining the Relationship Between PWV Change and eGFR Change Over Time in Chronic Kidney Disease Patients
Objective: This study aimed to investigate the longitudinal relationship between pulse wave velocity (PWV), a measure of arterial stiffness, and estimated glomerular filtration rate (eGFR), an indicator of renal function, in patients with chronic kidney disease (CKD). Methods: A total of 55 CKD patients (Stage 3–5), not on renal replacement therapy, were prospectively followed for approximately four years. PWV and eGFR were measured at baseline and at the end of follow-up. Patients were divided into two groups based on eGFR progression: stable and progressive decline. Demographic, clinical, and laboratory data were collected. The association between changes in PWV (ΔPWV) and eGFR (ΔeGFR) was analyzed. Results: No significant correlation was found between changes in PWV and changes in eGFR (P>.05). While there was a significant decline in eGFR in the progressive group compared to the stable group (P=.001), ΔPWV did not significantly differ between the groups. Variables such as age, blood pressure, and baseline PWV were not significantly different between groups. Parathormone and phosphorus levels were higher, and hemoglobin and albumin levels were lower in patients with eGFR progression. Conclusion: Over a four-year follow-up, changes in arterial stiffness (PWV) were not significantly associated with changes in renal function (eGFR) among CKD patients. The lack of correlation suggests that separate pathophysiological mechanisms may govern vascular stiffness and kidney function deterioration. Further studies, including molecular-level analyses, are required to clarify these complex interactions.
- 29 October 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (6) , 186-192
Assessing ciliary function in polycystic kidney disease: beyond the kidney
This study sought to investigate the effects of polycystic kidney disease and tolvaptan administration on mucociliary clearance. The cross-sectional study enrolled 30 patients with autosomal dominant polycystic kidney disease undergoing tolvaptan therapy, 30 patients with autosomal dominant polycystic kidney disease not on tolvaptan, and 30 healthy volunteers. Nasal mucociliary clearance time was determined using the saccharin transit time test, with a 1 mm diameter saccharin particle carefully placed on the anteromedial surface of the inferior nasal concha. Comparisons of mucociliary clearance time were then performed between the groups. In our study, the average mucociliary clearance time for patients with polycystic kidney disease was determined to be 9, in contrast to an average of 11 in the control group. A comparative analysis of patients receiving tolvaptan and those not receiving tolvaptan revealed an identical average mucociliary clearance time of 9 for both cohorts (p = 0.706). Furthermore, patients treated with tolvaptan demonstrated an average urine specific gravity of 1004, significantly lower than the 1011 observed in the non-tolvaptan group (p = 0.001). This study indicates that the administration of tolvaptan yielded a beneficial impact on hydration status; however, this improved hydration did not translate into a significant effect on mucociliary clearance. Furthermore, the mucociliary clearance times recorded in the patient group were found to be in alignment with those typically associated with chronic kidney disease cohorts.
- 29 October 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (6) , 186-192
Assessing ciliary function in polycystic kidney disease: beyond the kidney
This study sought to investigate the effects of polycystic kidney disease and tolvaptan administration on mucociliary clearance. The cross-sectional study enrolled 30 patients with autosomal dominant polycystic kidney disease undergoing tolvaptan therapy, 30 patients with autosomal dominant polycystic kidney disease not on tolvaptan, and 30 healthy volunteers. Nasal mucociliary clearance time was determined using the saccharin transit time test, with a 1 mm diameter saccharin particle carefully placed on the anteromedial surface of the inferior nasal concha. Comparisons of mucociliary clearance time were then performed between the groups. In our study, the average mucociliary clearance time for patients with polycystic kidney disease was determined to be 9, in contrast to an average of 11 in the control group. A comparative analysis of patients receiving tolvaptan and those not receiving tolvaptan revealed an identical average mucociliary clearance time of 9 for both cohorts (p = 0.706). Furthermore, patients treated with tolvaptan demonstrated an average urine specific gravity of 1004, significantly lower than the 1011 observed in the non-tolvaptan group (p = 0.001). This study indicates that the administration of tolvaptan yielded a beneficial impact on hydration status; however, this improved hydration did not translate into a significant effect on mucociliary clearance. Furthermore, the mucociliary clearance times recorded in the patient group were found to be in alignment with those typically associated with chronic kidney disease cohorts.
- 12 June 2025
- Published by Wiley in Therapeutic Apheresis and Dialysis
The Effect of Arteriovenous Fistula Creation on GFR Decline
Purpose: Chronic kidney disease (CKD) poses a significant public health challenge, severely affecting patients' quality of life. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend discussing renal replacement therapy options when patients reach CKD stage 4. Arteriovenous fistula (AVF) creation is considered the gold standard for vascular access in hemodialysis. This retrospective study aims to evaluate whether any changes in kidney function occur during the follow‐up period after AVF creation in patients with end‐stage kidney disease (ESKD).Methods: We analyzed data from 60 CKD patients who underwent AVF creation and were monitored in our nephrology outpatient clinics. Seventeen patients who consistently attended follow‐up visits were included for detailed analysis. We performed a retrospective review of laboratory and medical records from 6 months before and 6 months following AVF creation.Results: The cohort comprised 41.2% males, with a mean age of 62.4 years. The predominant underlying conditions were diabetes mellitus (58.8%), hypertension (29.4%), and polycystic kidney disease (11.8%). Statistical analysis of laboratory values before and after AVF creation (at 1, 3, and 6 months) revealed a significant decline in estimated glomerular filtration rate (eGFR) before AVF placement, followed by stabilization in the subsequent 6 months.Conclusion: The rate of eGFR decline was significantly reduced in CKD patients with AVF. This may be attributed to increased awareness of impending hemodialysis, leading to better dietary adherence and treatment compliance.
- 12 June 2025
- Published by Wiley in Therapeutic Apheresis and Dialysis
The Effect of Arteriovenous Fistula Creation on GFR Decline
Purpose: Chronic kidney disease (CKD) poses a significant public health challenge, severely affecting patients' quality of life. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend discussing renal replacement therapy options when patients reach CKD stage 4. Arteriovenous fistula (AVF) creation is considered the gold standard for vascular access in hemodialysis. This retrospective study aims to evaluate whether any changes in kidney function occur during the follow‐up period after AVF creation in patients with end‐stage kidney disease (ESKD).Methods: We analyzed data from 60 CKD patients who underwent AVF creation and were monitored in our nephrology outpatient clinics. Seventeen patients who consistently attended follow‐up visits were included for detailed analysis. We performed a retrospective review of laboratory and medical records from 6 months before and 6 months following AVF creation.Results: The cohort comprised 41.2% males, with a mean age of 62.4 years. The predominant underlying conditions were diabetes mellitus (58.8%), hypertension (29.4%), and polycystic kidney disease (11.8%). Statistical analysis of laboratory values before and after AVF creation (at 1, 3, and 6 months) revealed a significant decline in estimated glomerular filtration rate (eGFR) before AVF placement, followed by stabilization in the subsequent 6 months.Conclusion: The rate of eGFR decline was significantly reduced in CKD patients with AVF. This may be attributed to increased awareness of impending hemodialysis, leading to better dietary adherence and treatment compliance.
- Open Access
- 8 June 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Pre-earthquake kidney function is a predictor of outcomes in earthquake-related crush syndrome
The devastating earthquakes in Kahramanmaraş, Türkiye, in February 2024, caused extensive trauma and loss of lives, causing unique challenges in the management of earthquake-related crush syndrome. The current study investigates the prognostic value of pre-earthquake kidney function for mortality prediction in patients diagnosed with crush syndrome. A multi-center retrospective analysis was performed using data from 469 patients treated at 46 nephrology clinics. Pre-earthquake Kidney function, defined by serum creatinine and estimated glomerular filtration rate (eGFR) levels, was obtained from pre-earthquake health records. Clinical findings, laboratory parameters, complications, and survival probabilities were analyzed. Multivariate Cox regression was used to identify independent predictors of in-hospital mortality. The mean age of participants was 42.56 ± 16.92 years (Non-survivors: 50.46 ± 20.03 years, Survivors: 42.34 ± 16.80 years (p = 0.172)). The in-hospital mortality rate was 2.8%. Non-survivors exhibited significantly higher pre-earthquake creatinine levels than survivors (1.04 ± 0.61 mg/dL vs. 0.77 ± 0.33 mg/dL, p = 0.03), with lower eGFR (85.2 ± 34.7 mL/min/1.73 m² vs. 115.8 ± 39.4 mL/min/1.73 m², p = 0.008). Compared with survivors, non-survivors had higher incidences of AKI (92.3% vs. 61.6%, p = 0.037) and more severe metabolic disturbances, including hyperkalemia (5.41 ± 1.72 mmol/L vs. 5.13 ± 0.98 mmol/L, p = 0.008). Regression analysis revealed that pre-earthquake creatinine (HR: 9.121, 95% CI: 2.686–30.970, p < 0.001) and potassium levels at admission (HR: 3.338, 95% CI: 1.540–7.232, p = 0.002) were independent predictors of mortality. Pre-earthquake kidney function significantly predicts mortality in crush syndrome patients, highlighting the importance of baseline kidney assessment in disaster preparedness.
- 8 June 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Open AccessPre-earthquake kidney function is a predictor of outcomes in earthquake-related crush syndrome
The devastating earthquakes in Kahramanmaraş, Türkiye, in February 2024, caused extensive trauma and loss of lives, causing unique challenges in the management of earthquake-related crush syndrome. The current study investigates the prognostic value of pre-earthquake kidney function for mortality prediction in patients diagnosed with crush syndrome. A multi-center retrospective analysis was performed using data from 469 patients treated at 46 nephrology clinics. Pre-earthquake Kidney function, defined by serum creatinine and estimated glomerular filtration rate (eGFR) levels, was obtained from pre-earthquake health records. Clinical findings, laboratory parameters, complications, and survival probabilities were analyzed. Multivariate Cox regression was used to identify independent predictors of in-hospital mortality. The mean age of participants was 42.56 ± 16.92 years (Non-survivors: 50.46 ± 20.03 years, Survivors: 42.34 ± 16.80 years (p = 0.172)). The in-hospital mortality rate was 2.8%. Non-survivors exhibited significantly higher pre-earthquake creatinine levels than survivors (1.04 ± 0.61 mg/dL vs. 0.77 ± 0.33 mg/dL, p = 0.03), with lower eGFR (85.2 ± 34.7 mL/min/1.73 m² vs. 115.8 ± 39.4 mL/min/1.73 m², p = 0.008). Compared with survivors, non-survivors had higher incidences of AKI (92.3% vs. 61.6%, p = 0.037) and more severe metabolic disturbances, including hyperkalemia (5.41 ± 1.72 mmol/L vs. 5.13 ± 0.98 mmol/L, p = 0.008). Regression analysis revealed that pre-earthquake creatinine (HR: 9.121, 95% CI: 2.686–30.970, p < 0.001) and potassium levels at admission (HR: 3.338, 95% CI: 1.540–7.232, p = 0.002) were independent predictors of mortality. Pre-earthquake kidney function significantly predicts mortality in crush syndrome patients, highlighting the importance of baseline kidney assessment in disaster preparedness.